Approval

• The OssaTron is the only extracorporeal shock wave technology (ESWT) system approved by the U.S. Food and Drug Administration (FDA) for the treatment of multiple orthopedic conditions that have failed to respond to the conservative treatment. The OssaTron is approved to treat the four ligaments in the knee, chronic plantar fascitis (heel pain), and chronic lateral epicondylitis (tennis elbow).
  
  

Procedure

• The procedure happens in a doctor's office. Once anesthesia is administered to the targeted area, a high-viscosity ultrasound gel is applied to promote conductivity and enhance the effectiveness. The OssaTron application technician makes direct contact with the area and a shock wave is released. OssaTron treatment may cause the skin to redden, bruise, tingle or even tear. There may be temporary numbness, while some report residual pain after intense exercise or a full day of work.
  
  

Warning

• There is a controversy about the OssaTron, and a class action lawsuit has been filed against the manufacturer of the OssaTron. This lawsuit was brought forth because individuals believe that the manufacturers misrepresented or omitted to disclose material relating to the efficiency, testing and market acceptance of the OssaTron. According to the lawsuit, the manufacturer failed to disclose to investors that its own tests failed to support its statements that the OssaTron was safer, more effective and less costly than non-surgical, alternative treatments for knee and heel pain. Serious questions exist among the medical community concerning the effectiveness of extracorporeal shock wave treatment.